Monitor the Q1 2026 earnings call later today where Essig will address the leadership transition. Watch for any strategic or operational updates during the call.
Price Chart
Executive Summary
Integra LifeSciences announced that Chairman Stuart Essig has been appointed President and CEO, effective May 1, 2026, replacing Mojdeh Poul who departed April 30, 2026. The company also promoted Michael McBreen to the newly created role of Chief Commercial Officer. This is a return of a former CEO (1997-2012) who has been deeply involved as Executive Chairman, and the Board stated it is not an interim role and no CEO search is planned.
Key Facts
- Stuart Essig appointed President and CEO effective May 1, 2026, succeeding Mojdeh Poul who departed April 30, 2026
- Essig has served as Chairman since 2012 and was previously CEO from 1997 to 2012
- Board stated this is not an interim role and no CEO search is planned
- Michael McBreen appointed Chief Commercial Officer, a newly created role
- Essig receives $1,075,000 base salary, 125% target bonus, and $8,000,000 in one-time equity awards ($4M RSUs + $4M options)
- McBreen receives $660,000 base salary, 90% target bonus, and $1,000,000 in one-time equity awards
- Poul receives $566,526 lump sum cash payment plus up to $25,000 in legal fee reimbursement
Financial Impact
CEO transition costs include $8M in one-time equity grants to Essig and $1M to McBreen; Poul receives $566,526 cash severance
Risk Factors
- CEO transition may signal underlying operational or quality issues that prompted the change
- Essig's prior tenure ended in 2012 — the medtech landscape has changed significantly
- No financial guidance or performance metrics were provided in this filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000917520-26-000034 |
| Exhibit: ex991pressrelease_item502.htm | 0000917520-26-000034 |
| Document: 0000917520-26-000034-index-headers.html | 0000917520-26-000034 |
| Document: 0000917520-26-000034-index.html | 0000917520-26-000034 |
| Document: 0000917520-26-000034.txt | 0000917520-26-000034 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 8-K | $11.84 | awaiting T+5 | — | $12.12 (−2.36%) |
Oct 19, 2026 6d ago | 8-K | $13.33 | awaiting T+5 | — | $12.12 (−9.08%) |
Oct 14, 2026 12d ago | Court Ruling | $13.53 $12.33 | ▼ −8.91% | ▼ −7.89% | $12.12 (−10.42%) |
Oct 13, 2026 12d ago | 3 | $13.18 $11.84 | ▼ −10.13% | ▼ −10.59% | $12.12 (−8.01%) |
Oct 9, 2026 16d ago | 8-K | $13.98 $13.45 | ▲ +3.79% | ▲ +2.30% | $12.12 (+13.30%) |
Oct 6, 2026 20d ago | Press Release | $13.32 | awaiting T+5 | — | $12.12 (−9.01%) |
Oct 2, 2026 24d ago | 8-K | $12.68 $13.44 | ▼ −5.99% | ▼ −4.83% | $12.12 (+4.42%) |
Oct 2, 2026 24d ago | Press Release | $12.68 $13.44 | ▼ −5.99% | ▼ −4.83% | $12.12 (+4.42%) |
Sep 8, 2026 6w ago | 8-K | $16.26 $15.71 | ▼ −3.38% | ▼ −2.72% | $12.12 (−25.46%) |
May 8, 2026 24w ago | 8-K | $13.97 $14.11 | ▲ +1.00% | ▲ +1.09% | $12.12 (−13.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers